Back to discover
Disease

Conduct Disorder

Late-stage therapeutic developmentEmerging research
MeSHConduct Disorder
1
Publications
9
Clinical trials
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Clinical trials

7 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
9
All trials
0
Active
6
Late-stage
6
Completed
Late-stage studies

Open Label Trial of Aripiprazole in the Treatment of CD in Adolescents

Phase 4 · Completed · University of Iowa

Long-Term Lithium for Aggressive Conduct Disorder

Phase 3 · Completed · Drexel University

A Multi-center, Randomized, Double-blind, Cross-over, Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o. (300-1200 mg/Day) as Adjuvant Therapy for Impulsivity and Aggressive Behavior in Conduct Disorders in Adolescents

Phase 4 · Completed · Novartis

The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years

Phase 3 · Completed · Janssen Pharmaceutica N.V., Belgium

The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years

Phase 3 · Completed · Janssen Pharmaceutica N.V., Belgium

The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders

Phase 4 · Terminated · Sheba Medical Center
Recently completed

Open Label Trial of Aripiprazole in the Treatment of CD in Adolescents

Phase 4 · Completed · University of Iowa

Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders in Children and Adolescents - a Placebo Controlled, Randomized, Double Blind Clinical Trial

Phase 2 · Completed · University Hospital Freiburg

A Multi-center, Randomized, Double-blind, Cross-over, Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o. (300-1200 mg/Day) as Adjuvant Therapy for Impulsivity and Aggressive Behavior in Conduct Disorders in Adolescents

Phase 4 · Completed · Novartis

Long-Term Lithium for Aggressive Conduct Disorder

Phase 3 · Completed · Drexel University

The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years

Phase 3 · Completed · Janssen Pharmaceutica N.V., Belgium

The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years

Phase 3 · Completed · Janssen Pharmaceutica N.V., Belgium

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes2
  • Attention Deficit Disorder with Hyperactivity1
  • Conduct Disorder1
Leading journals1
  • JAMA network open1
Leading researchers8
  • Che Y1
  • Chen L1
  • Fang D1
  • Li Q1
  • Liang X1
  • Lu J1
  • Peng J1
  • Ran H1
Affiliations (unnormalised)4
  • Mental Health Institute of Yunnan1
  • NHC Key Laboratory of Drug Addiction Medicine1
  • The First Affiliated Hospital1
  • Yunnan Clinical Research Center for Mental Health1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A repetitive and persistent pattern of behavior in which the basic rights of others or major age-appropriate societal norms or rules are violated. These behaviors include aggressive conduct that causes or threatens physical harm to other people or animals, nonaggressive conduct that causes property loss or damage, deceitfulness or theft, and serious violations of rules. The onset is before age 18. (From DSM-IV, 1994)

Identifiers
MeSHConduct Disorder
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.